AYTU — Aytu BioPharma, Inc.

Aytu Biopharma Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: $12.4 million, down 33% from $18.5 million in Q3 2025.
• EXXUA Revenue: $2.4 million, representing a strong initial contribution from the product launched in December 2025.
• ADHD Portfolio Revenue: $9.1 million, down from $15.4 million, attributed to a strategic shift towards EXXUA and generic competition.
• Pediatric Portfolio Revenue: $0.9 million, down from $3.1 million, impacted by payer mix and increased returns.
• Gross Profit Margin: 61%, down from 69% year-over-year, affected by a $700,000 inventory write-down.
• Net Loss: $5.6 million, compared to a net income of $4 million in the prior year.
• Adjusted EBITDA: Negative $2.8 million, down from a positive $3.9 million year-over-year.
• Cash Position: $26.7 million as of March 31, 2026, down from $30 million at the end of 2025.

2. Strategic Updates and Business Highlights

• EXXUA Launch: The product is showing strong early adoption with over 1,300 prescriptions written in Q3 and continued growth into April (over 920 prescriptions).
• Sales Force Deployment: Only a partial quarter of full sales support was utilized, with significant growth expected as the sales team expands.
• RxConnect Program: Aimed at reducing barriers to access for patients, offering a no-cost 14-day titration pack and ensuring coverage for the first two months of therapy.
• Market Engagement: Over 450 unique prescribers have written prescriptions for EXXUA, indicating strong initial interest.
• Focus on High-Value Prescribers: The sales strategy is concentrated on targeted prescribers likely to adopt EXXUA.

3. Forward Guidance and Outlook

• Growth Expectations: Continued month-over-month prescription growth is anticipated as the sales force becomes fully operational and awareness increases.
• Investment Strategy: Planned increase in sales and marketing spend by $1 million to $2 million in Q4 2026 to drive awareness and adoption.
• Financial Model: Aiming for mid- to high 60% gross margins over time, with a disciplined approach to operating expenses.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Significant year-over-year revenue decline in both ADHD and Pediatric portfolios due to strategic shifts and market competition.
• Net Loss: The company reported a substantial net loss, raising concerns about profitability in the near term.
• Market Dynamics: The transition period for EXXUA may introduce variability in prescription and revenue patterns as payer dynamics settle.
• Dependency on EXXUA: The company is heavily reliant on the success of EXXUA for future growth, which poses risks if the launch does not meet expectations.

5. Notable Q&A Insights

• Stocking Revenue: Analysts estimated approximately $1.5 million in stocking revenue for EXXUA, which management confirmed as accurate.
• Patient Feedback: Positive anecdotes regarding EXXUA's efficacy, particularly concerning sexual side effects and weight gain, were highlighted, though long-term data is still pending.
• Prior Authorization Success: Over 70% of prior authorizations for EXXUA are being approved, indicating a favorable reimbursement landscape.
• Geographic Expansion: The company is considering expanding into new markets sooner than initially planned due to encouraging prescription activity in areas without a sales presence.

Overall, Aytu Biopharma is in a transitional phase with the launch of EXXUA showing promising early signs, although the company faces challenges with declining revenues from legacy products and the need for continued investment to support growth.